For patients with ESR1 mutations , newer oral selective estrogen receptor degraders (SERDs) like elacestrant are increasingly utilized. HER2-Positive SENORIF 2025-2026 - Institut Curie
Metastatic breast cancer (MBC) treatment has undergone a significant shift in 2026, moving from generic protocols toward precision medicine tailored to specific tumor subtypes and genetic mutations. While MBC remains a chronic condition requiring lifelong management rather than a curable one, modern therapeutic strategies aim to maximize survival and maintain high quality of life. Current Standards of Care (2026)
This remains the most common subtype, representing approximately 70–75% of cases.
Treatment decisions are primarily driven by the tumor's biological profile, specifically Hormone Receptor (HR) and HER2 status. HR-Positive, HER2-Negative (Luminal)
As of early 2026, the European Commission approved inavolisib (Itovebi) for use in combination with palbociclib and fulvestrant for advanced forms of the disease.